These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34254347)

  • 21. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development.
    Crisp A; Miller S; Thompson D; Best N
    Pharm Stat; 2018 Jul; 17(4):317-328. PubMed ID: 29635777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size determination for phase II studies of new vaccines.
    Rao MR; Blackwelder WC; Troendle JF; Naficy AB; Clemens JD
    Vaccine; 2002 Sep; 20(27-28):3364-9. PubMed ID: 12213406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunological surrogate endpoints to evaluate vaccine efficacy].
    Jin P; Li J; Zhou Y; Zhu F
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Dec; 49(12):1110-4. PubMed ID: 26887309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating a surrogate endpoint at three levels, with application to vaccine development.
    Gilbert PB; Qin L; Self SG
    Stat Med; 2008 Oct; 27(23):4758-78. PubMed ID: 17979212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian Phase II optimization for time-to-event data based on historical information.
    Bertsche A; Fleischer F; Beyersmann J; Nehmiz G
    Stat Methods Med Res; 2019 Apr; 28(4):1272-1289. PubMed ID: 29284369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of the effect size for sample size determination for a continuous response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD; Peduzzi PN
    Clin Trials; 2016 Jun; 13(3):275-85. PubMed ID: 26928986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian three-tier quantitative decision-making framework for single arm studies in early phase oncology.
    Liu Z; Liu J; Xia M
    J Biopharm Stat; 2023 Jan; 33(1):60-76. PubMed ID: 35723946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Better decision making in drug development through adoption of formal prior elicitation.
    Dallow N; Best N; Montague TH
    Pharm Stat; 2018 Jul; 17(4):301-316. PubMed ID: 29603614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovative trial designs and analyses for vaccine clinical development.
    Liu M; Li Q; Lin J; Lin Y; Hoffman E
    Contemp Clin Trials; 2021 Jan; 100():106225. PubMed ID: 33227451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of the treatment effect for sample size determination in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD; Makuch RW; Peduzzi PN
    Contemp Clin Trials; 2015 Mar; 41():160-71. PubMed ID: 25583273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.